EAST WINDSOR, N.Y., Aug 21 (Bernama-GLOBE NEWSWIRE) — ForDoz Pharma has entered into an agreement with Lupin, to market and distribute 2 complex injectable products in advanced development stage at ForDoz, in US and its territories. The products are in the Oncology and Anti-infective therapeutic areas which when approved, will provide affordable alternatives to patients and healthcare professionals.
These two licensed products are flagship technology assets among ForDoz complex injectable product pipeline portfolio including, liposome, microsphere, emulsion, nanocrystal, control release nanosuspension, and micelle. ForDoz is responsible for developing and obtaining necessary regulatory approvals. The products will be manufactured in ForDoz Pharma’s US based manufacturing site. Lupin shall be responsible for commercialization of the products. The deal terms are confidential.